A new pet for myeloma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Clinical journal of oncology nursing · 2011
   Article
2. Development of early treatment strategies for high-risk myeloma precursor disease in the future.Seminars in hematology · 2011
   Review
3. Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.Clinical lymphoma, myeloma & leukemia · 2010
   Review

Corrections and comments

• Comment on
  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.2009

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract